๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase I trials of WR2721 in combination with radiation therapy and with the alkylating agents cyclophosphamide and cis-platinum

โœ Scribed by Morton M. Kligerman; John H. Glick; Harold I. Amols; John M. Yuhas

Publisher
Elsevier Science
Year
1981
Tongue
English
Weight
106 KB
Volume
7
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase I clinical trial of combined thera
Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and cis-platinum (II) diaminedichloride (NSC 119875)
โœ Richard A. Ellerby; Hugh L. Davis Jr.; Fred J. Ansfield; Guillermo Ramirez ๐Ÿ“‚ Article ๐Ÿ“… 1974 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 438 KB

Thirty-one loading courses of 5-FU and cis-platinum (11) diaminedichloride (CPD) were given to 27 patients with a variety of malignancies. Up to 16 mg/kg/day of 5-FU and 2.5 mg/kg of the platinum were reached with minimal toxicity. Nausea (27/31) and vomiting (23/31) were the most frequent symptoms,

Bioreductive alkylating agent porfiromyc
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
โœ Bruce G. Haffty; Yung H. Son; Lynn D. Wilson; Rose Papac; Diana Fischer; Sara Ro ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 141 KB ๐Ÿ‘ 3 views

Porfiromycin (methyl mitomycin C) has been shown in laboratory studies to have increased preferential cytotoxicity to hypoxic cells and therefore may provide enhanced therapeutic efficacy over mitomycin C when used in combination with radiation therapy (RT). The purpose of the two clinical studies r